XAIR: Beyond Air, Inc. Stock

by  •  • Comments Off on XAIR: Beyond Air, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 17.92
Enterprise Value ($M) 22.83
Book Value ($M) 18.38
Book Value / Share 0.21
Price / Book 0.97
NCAV ($M) 3.58
NCAV / Share 0.04
Price / NCAV 5.00

Profitability (mra)
Return on Invested Capital (ROIC) -1.80
Return on Assets (ROA) -1.01
Return on Equity (ROE) -2.23

Liquidity (mrq)
Quick Ratio 3.12
Current Ratio 3.56

Balance Sheet (mrq) ($M)
Current Assets 19.34
Assets 34.14
Liabilities 15.76
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Balyasny Asset Management Llc 9.99
02-14 13G Alyeska Investment Group, L.P. 9.90
02-04 13G/A Avenue Venture Opportunities Fund, L.P. 8.86 -40.73

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-06-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-29 221,928 651,251 34.08
2025-04-28 691,686 2,123,793 32.57
2025-04-25 301,951 986,042 30.62
2025-04-24 459,685 1,725,679 26.64

(click for more detail)

Similar Companies
VANI – Vivani Medical, Inc. VERO – Venus Concept Inc.
VVOS – Vivos Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io